APPROACH AND METHODOLOGY
A. Site & Research Partner Selection
B. Collection of baseline data
C. Trial set up: The trial will consist of a 2 year follow-up of pig production (exotic cross breed) under 3 treatments. It will follow a longitudinal, prospective, single blind, and controlled study design. The prevalence of HAT will be tracked within the selected community to detect reduction in disease.
IMPLEMENTATION, TIMELINE, AND DELIVERABLES
This pilot has three main goals. The first objective is to assess the impact of the insecticidal Livestock Fence on pig productivity, feed requirements, and healthcare costs. This will be achieved through the assessment of a variety of productivity parameters, including weight gain, food intake, selected disease frequency, health status, and veterinarian interventions. The second goal is to estimate the cost-effectiveness of the insecticidal Livestock Fence treatment as compared to other treatments. This will be achieved by assessing the mechanical and biological performance of the Livestock Fence under field conditions. The pilot will also aim to quantify and price the labor and materials needed to install and maintain the fences. Lastly, the pilot aims to assess the impact of insecticidal Livestock Fence around pig pens and treated targets along rivers/ water bodies in selected communities on HAT prevalence. The pilot will compare the prevalence of HAT before and after the interventions.
Results of these interventions will be disseminated every 6 months through publications, farmer field days, and workshops over the 2 year pilot.
The Tsetse fly, Glossina species, is the vector of trypanosomiasis, also known as African sleeping sickness, for the human and animal disease (HAT & AAT). The DRC has the highest prevalence of HAT, accounting for more than 70% of cases reported worldwide (Pere P Simarro et al., 2010). Through reducing/removing the vector burden, both the human and animal diseases can be reduced and potentially eliminated. This has the dual effect of increasing agricultural outputs, and reducing disease burden on the population.
Currently, we are looking to expand the pilot and scale it out into other areas. This would also include a new tool that additionally protects people who contract sleeping sickness when they visit rivers and water sources. This tool is available and produced by Vestergaard and has been independently verified as effective by a BMGF project in Uganda.